These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 24813529)

  • 61. Feasibility of estimation of brain volume and 2-deoxy-2-(18)F-fluoro-D-glucose metabolism using a novel automated image analysis method: application in Alzheimer's disease.
    Musiek ES; Saboury B; Mishra S; Chen Y; Reddin JS; Newberg AB; Udupa JK; Detre JA; Hofheinz F; Torigian D; Alavi A
    Hell J Nucl Med; 2012; 15(3):190-6. PubMed ID: 23106049
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A study of plaque vascularization and inflammation using quantitative contrast-enhanced US and PET/CT.
    Hjelmgren O; Johansson L; Prahl U; Schmidt C; Fredén-Lindqvist J; Bergström GML
    Eur J Radiol; 2014 Jul; 83(7):1184-1189. PubMed ID: 24767629
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Validation of FDG uptake in the arterial wall as an imaging biomarker of atherosclerotic plaques with 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT).
    Bucci M; Aparici CM; Hawkins R; Bacharach S; Schrek C; Cheng S; Tong E; Arora S; Parati E; Wintermark M
    J Neuroimaging; 2014; 24(2):117-23. PubMed ID: 22928741
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology.
    Farid K; Poullias X; Alifano M; Regnard JF; Servois V; Caillat-Vigneron N; Petras S
    Nucl Med Commun; 2015 Jul; 36(7):722-7. PubMed ID: 25793929
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm.
    Brady MJ; Thomas J; Wong TZ; Franklin KM; Ho LM; Paulson EK
    Radiology; 2009 Feb; 250(2):523-30. PubMed ID: 19188319
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Methodologic Considerations for Quantitative 18F-FDG PET/CT Studies of Hepatic Glucose Metabolism in Healthy Subjects.
    Trägårdh M; Møller N; Sørensen M
    J Nucl Med; 2015 Sep; 56(9):1366-71. PubMed ID: 26159590
    [TBL] [Abstract][Full Text] [Related]  

  • 67. PET/MRI of metabolic activity in osteoarthritis: A feasibility study.
    Kogan F; Fan AP; McWalter EJ; Oei EHG; Quon A; Gold GE
    J Magn Reson Imaging; 2017 Jun; 45(6):1736-1745. PubMed ID: 27796082
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluation of Atlas-Based Attenuation Correction for Integrated PET/MR in Human Brain: Application of a Head Atlas and Comparison to True CT-Based Attenuation Correction.
    Sekine T; Buck A; Delso G; Ter Voert EE; Huellner M; Veit-Haibach P; Warnock G
    J Nucl Med; 2016 Feb; 57(2):215-20. PubMed ID: 26493207
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of FDG PET/MRI and FDG PET/CT in Pediatric Oncology in Terms of Anatomic Correlation of FDG-positive Lesions.
    Uslu-Beşli L; Atay Kapucu LÖ; Karadeniz C; Akdemir ÜÖ; Pinarli FG; Aydos U; Okur A; Kaya Z; Samanci C; Karabacak NI
    J Pediatr Hematol Oncol; 2019 Oct; 41(7):542-550. PubMed ID: 30933019
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT.
    Torigian DA; Lopez RF; Alapati S; Bodapati G; Hofheinz F; van den Hoff J; Saboury B; Alavi A
    Hell J Nucl Med; 2011; 14(1):8-14. PubMed ID: 21512658
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Use of Simultaneous 18F-FDG PET/MRI for the Detection of Spondylodiskitis.
    Fahnert J; Purz S; Jarvers JS; Heyde CE; Barthel H; Stumpp P; Kahn T; Sabri O; Friedrich B
    J Nucl Med; 2016 Sep; 57(9):1396-401. PubMed ID: 27199353
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
    Rahbar K; Seifarth H; Schäfers M; Stegger L; Hoffmeier A; Spieker T; Tiemann K; Maintz D; Scheld HH; Schober O; Weckesser M
    J Nucl Med; 2012 Jun; 53(6):856-63. PubMed ID: 22577239
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Is liver SUV stable over time in ¹⁸F-FDG PET imaging?
    Laffon E; Adhoute X; de Clermont H; Marthan R
    J Nucl Med Technol; 2011 Dec; 39(4):258-63. PubMed ID: 21878481
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?
    Regier M; Derlin T; Schwarz D; Laqmani A; Henes FO; Groth M; Buhk JH; Kooijman H; Adam G
    Eur J Radiol; 2012 Oct; 81(10):2913-8. PubMed ID: 22197090
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
    Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Correcting tumour SUV for enhanced bone marrow uptake: retrospective 18F-FDG PET/CT studies.
    Teo BK; Badiee S; Hadi M; Lam T; Johnson L; Seo Y; Bacharach SL; Hasegawa BH; Franc BL
    Nucl Med Commun; 2008 Apr; 29(4):359-66. PubMed ID: 18317301
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.
    Imbriaco M; Caprio MG; Limite G; Pace L; De Falco T; Capuano E; Salvatore M
    AJR Am J Roentgenol; 2008 Nov; 191(5):1323-30. PubMed ID: 18941064
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical Evaluation of Zero-Echo-Time Attenuation Correction for Brain 18F-FDG PET/MRI: Comparison with Atlas Attenuation Correction.
    Sekine T; Ter Voert EE; Warnock G; Buck A; Huellner M; Veit-Haibach P; Delso G
    J Nucl Med; 2016 Dec; 57(12):1927-1932. PubMed ID: 27339875
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The influence of different contrast medium concentrations and injection protocols on quantitative and clinical assessment of FDG-PET/CT in lung cancer.
    Verburg FA; Kuhl CK; Pietsch H; Palmowski M; Mottaghy FM; Behrendt FF
    Eur J Radiol; 2013 Oct; 82(10):e617-22. PubMed ID: 23880426
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.